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Abstract
In order to assess the significance of drug/substance levels measured in intensive care medicine and clinical and
forensic toxicology as well as for therapeutic drug monitoring, it is essential that a comprehensive collection of data
is readily available. We revisited and expanded our 2012 compilation of therapeutic and toxic plasma concentration
ranges as well as half-lives of now more than 1100 drugs and other xenobiotics.
Data have been abstracted from original papers, text books, and previous compilations and have been completed
with data collected in our own forensic and clinical toxicology laboratories. We compiled the data presented in the
table and the corresponding annotations over the past 30+ years. A previous compilation was completely double-
checked, revised, and updated, if necessary. In addition, more than 200 substances, especially drugs who have been
introduced since 2012 to the market as well as illegal drugs and other xenobiotics which became known to cause
intoxications were added. We carefully referenced all data. Moreover, the annotations providing details were
updated and revised, when necessary.
For more than 1100 drugs and other xenobiotics, therapeutic (“normal”) and, if data was available, toxic, and
comatose-fatal plasma/blood concentrations as well as elimination half-lives were compiled in a table.
In case of intoxications, the blood concentration of the substance and/or metabolite better predicts the clinical
severity of the case when compared to the assumed amount and time of ingestion. Comparing and contrasting
the clinical case against the data provided, including the half-life, may support the decision for or against further
intensive care. In addition, the data provided are useful for the therapeutic monitoring of pharmacotherapies, to
facilitate the diagnostic assessment and monitoring of acute and chronic intoxications as well as to support forensic
and clinical expert opinions.
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Introduction
Drug overdose has become the leading cause of death
from injury in the USA [1]. In 2017, more than 2.6 mil-
lion closed encounters were logged by the American As-
sociation of Poison Control Centers’ National Poison
Data System and 2.12 million were related to human ex-
posures. Although the total encounters showed a 3.8%
decline from 2016, human exposures with more serious
outcomes increased 3.1%. Consistent with previous
years, the top five substance classes most frequently in-
volved in all human exposures included three drug clas-
ses: analgesics (11.1%), household cleaning substances
(7.4%), cosmetics/personal care products (6.8%), seda-
tives/hypnotics/antipsychotics (5.7%), and antidepres-
sants (5.0%) [2]. According to the UK’s National Poisons
Information Service Annual Report 2017/2018, around
160,000 hospital presentations occur annually as a result
of poisoning, most frequently in the context of deliberate
self-harm [3].
In case of intoxication or poisoning, the concentration
of the ingested substance and/or metabolite in plasma/
serum better predicts the clinical severity of the case and
the potential outcome when compared to the assumed
amount and time of ingestion. In addition, it is recom-
mended that plasma concentrations of drugs having a
narrow therapeutic range or with a highly variable re-
sponse (such as in psychiatry) have to be measured and
monitored. Apart from acute and chronic intoxications,
it is indicated to draw blood samples for the following
reasons: if doses are high and borderline, if signs of
over-dosage occur although the dose is within normal
range (e.g. genetic polymorphism), if there is no efficacy
although the dose is correct, or if medication non-
adherence can be expected [4].
In general, blood concentrations of drugs at steady
state are retrievable from the dosage and pharmacoki-
netic data. However, sufficient pharmacokinetic data are
often not available. Moreover, searching, retrieving,
reading, analysing, and interpreting the relevant pharma-
cological, toxicological, and critical care literature in case
of acute intoxications in daily intensive care practice are
time-consuming and may delay or even mislead optimal
clinical decisions. Therefore, it makes sense to offer a
carefully referenced compilation of therapeutic and toxic
plasma concentration ranges, as well as half-lives, of a
large number of drugs and other xenobiotics for quick
and comprehensive information [4].
Materials and methods
The data presented in the table and the corresponding
annotations (Additional file 1) have been developed over
the past 30+ years. A previous compilation [4] has been
completely revised and updated where necessary. In
addition, more than 200 substances, especially drugs that
have been introduced since then were added. Further-
more, we included new psychoactive substances (NPS),
marketed as ‘legal highs’, as well as other illegal drugs
which became known to cause intoxications. All data
were carefully referenced. Moreover, the annotations
providing details were updated and revised, if necessary.
Reviews, text books, compilations of other authors
(mainly [5–25]), and most importantly, original publica-
tions concerning individual drugs, pharmacokinetic
studies, and case reports have been used to set up and
keep the database updated. Experience gained over more
than 30 years from working in the clinical and forensic
toxicological field contributed to the data presented.
The substances were selected by clinical and toxico-
logical aspects, by frequency of prescribing or (mis-)use
and other matters in the area of intensive care medicine
as well as clinical and forensic toxicology.
The following clinical categories were used for group-
ing analytical data:
Therapeutic: blood (plasma or serum) concentrations
observed following therapeutically effective doses; no or
only minimal side effects (drugs); “normal”:
concentrations associated with no or only minimal
toxic effects (other xenobiotics or environmental
exposure) or achieved by a typical dosing regimen
(illegal drugs).
Toxic: blood (plasma/serum) concentrations producing
toxicity or clinically relevant adverse effects.
Comatose-fatal: blood (plasma/serum for comatose)
concentrations and whole blood (for fatal)
concentrations reported to have caused coma and
death, respectively. Whether published data for deaths
refer to levels measured ante-mortem or post-mortem
(femoral or heart blood) is, however, often unknown.
Results and discussion
For more than 1100 drugs and other xenobiotics, thera-
peutic (“normal”) and, if data was available, toxic, and
comatose-fatal plasma/blood concentrations and elimination
half-lives were compiled in one table (Additional file 1).
The compilation includes data for centrally active sub-
stances (e.g. anaesthetics, antidepressants, antiepileptics,
antiparkinson drugs, antipsychotics, anxiolytics, hypnotics,
lithium, opioids, sedatives, stimulants), cardiovascular
drugs (e.g. angiotensin-converting enzyme inhibitors,
angiotensin receptor antagonists [sartanes], antiarrhyth-
mics, anticoagulants, antihypertensives, antiplatelets, beta
blockers, calcium-channel blockers, cardiac glycosides, di-
uretics, lipid lowering drugs, nitrates), antimicrobial agents
(e.g. antibiotics, antimalarials, antimycotics, antiretrovir-
als), and anabolics, non-opioid analgesics including non-
steroidal anti-inflammatory drugs, antiasthmatics, antican-
cer drugs, antidiabetics, antihistamines, corticosteroids,
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immunosuppressants, local anaesthetics, muscle relaxants,
phosphodiesterase inhibitors, and vitamins, among others
(Fig. 1).
In addition and if data were available, other relevant
xenobiotics such as controlled substances, illegal and
recreational drugs, including new psychoactive sub-
stances, heavy metals, and pesticides, among others were
listed.
To the best of our knowledge, this compilation is the
most current and comprehensive single source of data,
necessary to support the clinical decision-making and
assessing blood concentrations in case of acute or
chronic intoxications. Inter-individual deviation is, how-
ever, high. Therefore, any data listed can only be taken
as an orientation.
Often, it is not possible to find the threshold between
the therapeutic and toxic concentration for the specific
patient. This is for instance the case if tolerance (espe-
cially true for all opioids), drug/drug-interactions, or
additional diseases are involved. In order to keep the
overall context clear, we preferred not to go into further
details.
Many data about “comatose” or even “fatal” plasma/blood
concentrations are consciously oriented on life threatening
or lethal intoxications where low plasma/blood concentra-
tions were detected. Considering these data may prevent
underestimation of actual or potential dangers in clinical
cases. Many intoxicated patients survived even with signifi-
cantly higher plasma concentrations.
It is also difficult to relate the concentrations to the
clinical picture because the interval between intake of
the drug and drawing a blood sample is frequently un-
known. In any case, it is more reliable to have the cor-
rect concentration measured rather than assuming how
much drug/substance has been taken.
For a variety of data representing lethal cases, it is not
known whether ante- or post-mortem, that is, (venous)
femoral or heart blood levels were measured. If this in-
formation is unknown, we refrained from mentioning
this detail.
Elimination half-lives are statistically more reliable
than data gathered in case of intoxications. Yet even
with this data, substantial deviation occurs. In addition,
most pharmacokinetic parameters are retrieved from
healthy subjects after application of relatively low doses.
The data indicated generally deals with the terminal
elimination half-life.
Conclusions
In case of acute or chronic intoxications, the concentra-
tion of the ingested substance and/or metabolite in
blood much better predicts the clinical severity of the
case when compared to the assumed amount and time
of ingestion. Comparing and contrasting the clinical case
against the data provided, including the half-life, may
support the decision for or against further intensive care.
In addition, the data provided are useful for the thera-
peutic monitoring of pharmacotherapies, to facilitate the
diagnostic assessment and monitoring of acute and
chronic intoxications as well as to support forensic and
clinical expert opinions.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13054-020-02915-5.
Additional file 1. Therapeutic (“normal”), toxic, and comatose-fatal
blood-plasma concentrations (mg/L, if not stated otherwise) in man. A
table containing data for more than 1100 drugs and other xenobiotics in
man including annotations and references.
Fig. 1 Summary findings
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